LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Closed

SectorHealthcare

22.87 -1.63

Buy Sell

Overview

Share price change

24h

Current

Min

22.4

Max

23.25

Key metrics
By Trading Economics
Income	-2.8M -57M
Sales	35K 730K
Profit margin	-7,753.425
Employees	186
EBITDA	-1.1M -63M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+111.52% upside

Dividends
By Dow Jones
Next Earnings	11 Nov 2025

Market Stats
By TradingEconomics
Market Cap	196M 1.6B
Previous open	24.5
Previous close	22.87

News Sentiment

By Acuity

100%

363 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Nov 2025, 21:06 UTC

Major Market Movers

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 Nov 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 Nov 2025, 22:22 UTC

Earnings

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 Nov 2025, 22:03 UTC

Earnings

Constellation Software 3Q Rev $2.95B >CSU.T

7 Nov 2025, 22:03 UTC

Earnings

Constellation Software 3Q Net $210M >CSU.T

7 Nov 2025, 22:03 UTC

Earnings

Constellation Software 3Q EPS $9.89 >CSU.T

7 Nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7 Nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7 Nov 2025, 20:59 UTC

Earnings

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 Nov 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 Nov 2025, 20:22 UTC

Earnings

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 Nov 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7 Nov 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7 Nov 2025, 19:31 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 Nov 2025, 19:17 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 Nov 2025, 19:09 UTC

Earnings

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 Nov 2025, 19:08 UTC

Earnings

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 Nov 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 Nov 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

7 Nov 2025, 17:17 UTC

Acquisitions, Mergers, Takeovers

Satair Expects to Complete Purchase in Early 2026

7 Nov 2025, 17:17 UTC

Acquisitions, Mergers, Takeovers

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 Nov 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 Nov 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

7 Nov 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 Nov 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 Nov 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

111.52% upside

12 Months Forecast

Average 49.2 USD 111.52%

High 67 USD

Low 25 USD

Based on 12 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.